Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrotinib in HER2+ and HR+ Metastatic Breast Cancer
NCT03910712Phase 2Unknown
- Sponsor
- Peking Union Medical College Hospital
- Start
- Jun 2019
- Primary completion
- Jun 2022
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
01
Overview
Phase 2, randomised, open-label trial of pyrotinib in HER2-positive breast cancer, Hormone-Receptor-Positive Breast Cancer and breast cancer, sponsored by Peking Union Medical College Hospital. Status: unknown.
02
Drugs
pyrotinib
03
Conditions
HER2-positive breast cancerHormone-Receptor-Positive Breast Cancerbreast cancer
Beyond the preview
Go deeper on NCT03910712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03910712.